A one-size-fits-all approach to alternative payment models (APMs) often isn’t very fair to community practices, said Miriam Atkins, MD, FACP, president of the Community Oncology Alliance.
Alternative payment models that treat all practices the same or don’t account for variations aren’t very fair, particularly to community oncology practices, said Miriam Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Atkins was just reelected to a second consecutive term as president.
Transcript
As COA president during the transition from OCM to the EOM, which started July 1, how do you envision leveraging your position to foster collaboration, resilience, and innovation within the community oncology sector?
As the president of COA, I don't think I can really leverage my position for that. The issue with OCM [Oncology Care Model] and EOM [Enhancing Oncology Model], one thing is, my practice was with OCM for a short period of time, and we ended up getting out of it because we had physicians with different tax ID numbers, and that's not qualified [so we had] to get out for that.
But [another] issue is, we had to hire extra staff for the information that [CMS] wanted, and we're already short on staff. So, given the little staff, we had more responsibilities. And the other issue is, we get the MEOS [Monthly Enhanced Oncology Services] payment or a payment, and then [CMS] decides, well, “you didn't meet the criteria, so we're going to take it back.” That's very frustrating, and it doesn't leave us much confidence in how fair this will actually be to community practices.
How can we hope to innovate for the future if at present, practices can’t agree on a suitable alternative payment model to keep community oncology care affordable, reimbursable, and within the community?
One big issue would be to make the reimbursement fair. As long as the hospital can get paid 2 or 3 times more than I can, it's going to make it harder to keep my doors open. The other issue about the payment models is every practice is different, and every state is different. So, it's not one size fits all.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More